Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Wells Pharma of Houston LLC
WARNING LETTER
•Wells Pharma of Houston LLC•March 28, 2025

Wells Pharma of Houston LLC – FDA Warning Letter, Mar 28, 2025

Record Details

The FDA issued a Warning Letter to Wells Pharma of Houston, LLC on November 7, 2025, following an inspection from March 17 to March 28, 2025. The letter identifies serious deficiencies, placing patients at risk, and states that drug products produced by the company failed to meet the conditions for outsourcing facilities under Section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA).Key violations include the failure to properly label compounded drugs with the required "This is a compounded drug" statement and inadequate procedures for submitting adverse event reports, specifically lacking a complete definition of "serious" adverse events. Consequently, the company"s drug products are not eligible for exemptions from FDA approval requirements, adequate directions for use labeling, and Drug Supply Chain Security Act provisions.Furthermore, the FDA found drug products to be adulterated due to insanitary conditions and numerous Current Good Manufacturing Practice (CGMP) violations. Insanitary conditions observed included operators blocking critical airflow, media fills not performed under challenging conditions, inadequate smoke studies, and cracked/discolored plexiglass in sterile areas. CGMP violations encompassed a failure to establish procedures preventing microbiological contamination, inadequate environmental monitoring, insufficient investigation of discrepancies, deficient quality control, and poor labeling control. The company must implement comprehensive corrective actions to address these serious issues and comply with regulatory standards.

Company
Wells Pharma of Houston LLC
Inspection date
March 28, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • F. Gail Bormel (F.)
View Company Profile

ID · 6655374e-2534-4052-8d90-44d11d8f1997

Violation Codes10
21 U.S.C. 351(a)(2)(B)FD&C Act 501(a)(2)(B)FD&C Act 505(a)FD&C Act 301(d)21 U.S.C. 331(k)FD&C Act 301(a)FD&C Act 502(f)(1)FD&C Act 301(k)FD&C Act 501(a)(2)(A)FD&C Act 505

Full citation text and observation details available on the Dashboard.

Other documents for Wells Pharma of Houston LLC
  • 483 - 2026-04-14April 14, 2026
  • 483 - 2025-03-28March 28, 2025
  • 483 - 2022-12-14December 14, 2022
  • 483 - 2021-06-17June 17, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Wells Pharma of Houston LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.